Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Aggarwal C, Maity AP, Bauml JM, Long Q, Aleman T, Ciunci C, D'Avella C, Volpe M, Anderson E, Jones LM, Sun L, Singh AP, Marmarelis ME, Cohen RB, Langer CJ, Amaravadi R. Aggarwal C, et al. Among authors: langer cj. Oncologist. 2023 Jul 5;28(7):644-e564. doi: 10.1093/oncolo/oyad106. Oncologist. 2023. PMID: 37186063 Free PMC article. Clinical Trial.
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Kramer NM, Horwitz EM, Cheng J, Ridge JA, Feigenberg SJ, Cohen RB, Nicolaou N, Sherman EJ, Babb JS, Damsker JA, Langer CJ. Kramer NM, et al. Among authors: langer cj. Head Neck. 2005 May;27(5):406-14. doi: 10.1002/hed.20163. Head Neck. 2005. PMID: 15719391 Clinical Trial.
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D. Cohen RB, et al. Among authors: langer cj. Cancer Chemother Pharmacol. 2007 Jun;60(1):81-9. doi: 10.1007/s00280-006-0352-0. Epub 2006 Oct 10. Cancer Chemother Pharmacol. 2007. PMID: 17031646 Clinical Trial.
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
Huang CH, Millenson MM, Sherman EJ, Borghaei H, Mintzer DM, Cohen RB, Staddon AP, Seldomridge J, Treat OJ, Tuttle H, Ruth KJ, Langer CJ. Huang CH, et al. Among authors: langer cj. J Thorac Oncol. 2008 Sep;3(9):1032-8. doi: 10.1097/JTO.0b013e31818307c2. J Thorac Oncol. 2008. PMID: 18758307 Free article. Clinical Trial.
Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Borghaei H, et al. Among authors: langer cj. J Thorac Oncol. 2008 Nov;3(11):1286-92. doi: 10.1097/JTO.0b013e318189f50e. J Thorac Oncol. 2008. PMID: 18978564 Free article. Clinical Trial.
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Borghaei H, et al. J Clin Oncol. 2009 Sep 1;27(25):4116-23. doi: 10.1200/JCO.2008.20.2515. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636016 Free PMC article. Clinical Trial.
344 results